Global Pharmaceutical Solid Dosage Contract Manufacturing Market to Grow at a CAGR of 6.3% by 2030

The global pharmaceutical solid dosage contract manufacturing market size was valued at USD 30.1 Billion in 2022 and is further predicted to reach USD 55.3 Billion by 2030, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period.

Pharmaceutical solid dosage contract manufacturing involves outsourcing the manufacturing of tablets, capsules, and other solid dosage forms to third-party contract manufacturing organizations (CMOs). These CMOs specialize in the manufacturing, packaging, and labeling of pharmaceutical products for pharmaceutical companies. By outsourcing these services, pharmaceutical companies can focus on their core competencies, such as research and development, and reduce their capital expenditures.

The global pharmaceutical solid dosage contract manufacturing market is driven by various factors. One of the main drivers is the increasing demand for pharmaceuticals worldwide, which is fueled by factors such as an aging population and a growing incidence of chronic diseases. The need for cost-effective solutions is also driving the market, as pharmaceutical companies seek to reduce their capital expenditures and focus on core competencies such as research and development. Technological advancements such as automation and continuous manufacturing are also driving the market, as they offer potential cost savings and improved efficiency.

The market presents several opportunities for growth. The trend towards outsourcing and the need for specialized formulations and personalized medicine provide opportunities for contract manufacturers to expand their client base. Additionally, the growing importance of biologics and biosimilars in the pharmaceutical industry presents an opportunity for contract manufacturers to develop and expand their capabilities in this area. Advancements in technology, such as automation and continuous manufacturing, provide opportunities for contract manufacturers to improve efficiency and reduce costs. 

However, the pharmaceutical solid dosage contract manufacturing industry also faces several restraints. Regulatory hurdles and compliance requirements can be time-consuming and costly. Increasing competition and pricing pressures can make it difficult for some contract manufacturers to stay competitive. Supply chain disruptions and the need for significant investments in equipment and facilities are also potential restraints.

The global pharmaceutical solid dosage contract manufacturing market is segmented based on product type, drug release pattern, and region.

Based on product type, the market is bifurcated into tablets, capsules, powder, lozenge, and others. The tablets segment held the largest market share in 2022 and is further predicted to grow rapidly at a remarkable CAGR during the forecast period. This is mainly due to the increased popularity of tablets as a preferred dosage form by patients due to their ease of administration, portability, and convenience. Tablets also offer better stability and longer shelf life compared to other solid dosage forms, making them an attractive option for pharmaceutical companies. Additionally, tablets can be produced at a larger scale, allowing for cost savings through economies of scale. These factors drive the growth of the segment during the forecast period.

Based on drug release pattern, the market is segmented into instant release, sustained release, extended release, effervescent tablets, chewable tablets, and enteric release. The sustained release segment held the dominating market share in 2022 and is further predicted to cite the fastest CAGR during the forecast period. The growth of the segment is mainly due to increasing demand for medications that provide a slow and steady release of the active ingredient over an extended period. Sustained-release formulations allow for reduced dosing frequency, better patient compliance, and improved therapeutic outcomes. These formulations are particularly useful for chronic conditions that require continuous medication and where it may be difficult for patients to adhere to a dosing regimen. In addition, sustained-release formulations can also reduce the risk of side effects and toxicity associated with high doses of medication, as they release the active ingredient slowly over time. This has led to increased interest from pharmaceutical companies and healthcare providers in developing sustained-release formulations for a variety of therapeutic areas, including cardiovascular disease, diabetes, and pain management. These factors further drive the growth of the segment during the forecast period.

Based on region, the North American region held the largest pharmaceutical solid dosage contract manufacturing market share in 2022 and is further predicted to grow at a significant CAGR during the forecast period. Factors driving this growth include increasing demand for generic drugs, rising healthcare costs, and a growing aging population. Additionally, outsourcing manufacturing to contract manufacturers allows pharmaceutical companies to focus on their core competencies, reduce costs, and improve operational efficiency. The COVID-19 pandemic has also led to an increased demand for certain medications, further boosting the growth of the contract manufacturing market. These factors drive the growth of the market in the region during the forecast period.

This review is based on a report by Zion Market Research, titled “Pharmaceutical Solid Dosage Contract Manufacturing Market By Product Type (Tablets, Capsule, Lozenge, Powder, And Others), By Drug Releases Pattern (Instant Release, Sustained Release, Extended Release, Effervescent Tablets, Chewable Tablets, Enteric Release), By Region– Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts, 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/pharmaceutical-solid-dosage-contract-manufacturing-market

Recent Developments

• In November 2021, Catalent announced the acquisition of RheinCell Therapeutics, a German-based cell therapy company. The acquisition will help Catalent expand its capabilities in the cell and gene therapy space, which is a growing area of the pharmaceutical industry. Additionally, in January 2022, Catalent announced plans to invest $100 million in expanding its biologics manufacturing facility in Wisconsin, USA. This expansion will help Catalent meet the increasing demand for biologics manufacturing services.
• In September 2021, Lonza announced the expansion of its cell and gene therapy manufacturing facility in Pearland, Texas. The expansion will double the facility's manufacturing capacity and is expected to be completed in 2023. Additionally, in October 2021, Lonza announced a collaboration with Cryoport, a logistics company specializing in cell and gene therapies, to provide end-to-end supply chain solutions for the industry.

The global pharmaceutical solid dosage contract manufacturing market is dominated by players such as:

• HAUPT Pharma AG
• Abbott Laboratories
• NextPharma
• Catalent Pharma Solutions
• Althea Technologies
• Jubilant Life Sciences Limited
• Royal DSM N.V and Nipro Corp. Aenova
• Alkermes plc
• Associates of Cape Cod Inc.
• BioPharma Solutions
• Coldstream Laboratories Inc.
• Covance Inc.
• Cytovance Biologics Inc.
• Dalton Pharma Services
• DPT Laboratories
• Emergent BioSolutions Inc.
• Fresenius Kabi
• Grand River Aseptic Manufacturing (GRAM)
• Halo Pharmaceutical
• IGI Laboratories
• Lyophilization Technology Inc.
• Metrics Inc.
• Mikart Inc.
• Patheon Inc.
• Pillar5 Pharma Inc.
• Velesco Pharma

The global pharmaceutical solid dosage contract manufacturing market is segmented as follows:

By Product Type

• Tablets
• Capsule
• Lozenge
• Powder

By Drug Releases Pattern

• Instant Release
• Sustained Release
• Extended Release
• Effervescent Tablets
• Chewable Tablets
• Enteric Release

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com